aspirin has been researched along with Seizures in 55 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Seizures: Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Administration of aspirin with a dosage of 60 mg or 80 mg/kg initiated at 2 months after pilocarpine-induced status epilepticus significantly reduced the frequency and duration of spontaneous recurrent seizures." | 7.85 | Aspirin attenuates spontaneous recurrent seizures in the chronically epileptic mice. ( Hu, M; Liu, JX; Liu, Y; Yuan, B; Zhu, K, 2017) |
| " Here, we examined the anti-epileptogenic effect and possible mechanisms of aspirin, a non-selective Cyclooxygenase (COX) inhibitor, in a rat model of lithium-pilocarpine-induced status epilepticus (SE)." | 7.78 | Aspirin attenuates spontaneous recurrent seizures and inhibits hippocampal neuronal loss, mossy fiber sprouting and aberrant neurogenesis following pilocarpine-induced status epilepticus in rats. ( Cui, XL; Jiang, W; Li, XW; Ma, L; Wang, Y; Wei, D; Yang, F, 2012) |
| " The objective of our study was to investigate the possible neuroprotective effects of sodium salicylate in vivo in rats with kainic acid-induced seizures, a model for temporal lobe epilepsy in human patients." | 7.70 | The aspirin metabolite sodium salicylate causes focal cerebral hemorrhage and cell death in rats with kainic acid-induced seizures. ( Mamelak, AN; Najbauer, J; Schuman, EM, 2000) |
| "The patient has remained seizure-free for 23 months and demonstrated an excellent response to pulsed dye laser treatment." | 6.61 | Preventive treatment with oral sirolimus and aspirin in a newborn with severe Sturge-Weber syndrome. ( López-Gutiérrez, JC; Sánchez-Carpintero, I; Triana Junco, PE, 2019) |
| "Aspirin has shown promise as an anticonvulsant drug in animal models." | 5.39 | Does aspirin use make it harder to collect seizures during elective video-EEG telemetry? ( Caylor, LM; Doherty, MJ; Godfred, RM; Haltiner, AM; Parikh, MS; Sepkuty, JP, 2013) |
| "In MES seizures significant protection was seen with aspirin 100 mg/kg where as higher dose of aspirin 500 mg/kg was required to elicit maximum protection against PTZ seizures." | 5.31 | Aspirin modulates the anticonvulsant effect of diazepam and sodium valproate in pentylenetetrazole and maximal electroshock induced seizures in mice. ( Gupta, YK; Srivastava, AK, 2001) |
| "Tranexamic acid reduces the risk of bleeding among patients undergoing cardiac surgery, but it is unclear whether this leads to improved outcomes." | 5.24 | Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery. ( Bussières, JS; Byrne, K; Chan, MT; Cooper, DJ; Forbes, A; Jayarajah, M; Landoni, G; Marasco, S; McGuinness, S; McNeil, J; Myles, PS; Painter, T; Silbert, B; Smith, JA; Wallace, S, 2017) |
| "Administration of aspirin with a dosage of 60 mg or 80 mg/kg initiated at 2 months after pilocarpine-induced status epilepticus significantly reduced the frequency and duration of spontaneous recurrent seizures." | 3.85 | Aspirin attenuates spontaneous recurrent seizures in the chronically epileptic mice. ( Hu, M; Liu, JX; Liu, Y; Yuan, B; Zhu, K, 2017) |
| " Here, we examined the anti-epileptogenic effect and possible mechanisms of aspirin, a non-selective Cyclooxygenase (COX) inhibitor, in a rat model of lithium-pilocarpine-induced status epilepticus (SE)." | 3.78 | Aspirin attenuates spontaneous recurrent seizures and inhibits hippocampal neuronal loss, mossy fiber sprouting and aberrant neurogenesis following pilocarpine-induced status epilepticus in rats. ( Cui, XL; Jiang, W; Li, XW; Ma, L; Wang, Y; Wei, D; Yang, F, 2012) |
| " The objective of our study was to investigate the possible neuroprotective effects of sodium salicylate in vivo in rats with kainic acid-induced seizures, a model for temporal lobe epilepsy in human patients." | 3.70 | The aspirin metabolite sodium salicylate causes focal cerebral hemorrhage and cell death in rats with kainic acid-induced seizures. ( Mamelak, AN; Najbauer, J; Schuman, EM, 2000) |
| " Nicardipine remarkably inhibited epileptic seizures induced by combined treatment with enoxacin (p." | 3.69 | Epileptogenic activity induced by combined treatment with antiinflammatory drugs and enoxacin and its inhibition by a calcium antagonist, nicardipine. ( Kamei, C; Kitazumi, K; Ohishi, H; Okumura, Y; Sugimoto, Y, 1996) |
| "The effects of centrally injected prostaglandins (PGE1 and PGF2 alpha), arachidonic acid and lysine acetylsalicylate were examined on the seizure activity and temperature changes produced by pentylentetrazole (PTZ) and also on maximal electroshock (MES) seizures." | 3.66 | Modification of convulsive behaviour and body temperature in mice by intracerebroventricular administration of prostaglandins, arachidonic acid and the soluble acetylsalicylic acid salt lysine acetylsalicylate. ( Climax, J; Sewell, RD, 1981) |
| "The patient has remained seizure-free for 23 months and demonstrated an excellent response to pulsed dye laser treatment." | 2.61 | Preventive treatment with oral sirolimus and aspirin in a newborn with severe Sturge-Weber syndrome. ( López-Gutiérrez, JC; Sánchez-Carpintero, I; Triana Junco, PE, 2019) |
| "Seizures are rare manifestation of thalamic disorder." | 1.46 | Unilateral Thalamic Infarct Presenting as a Convulsive Seizure. ( Brohi, H; Kumar, R; Mughul, A, 2017) |
| "Aspirin has shown promise as an anticonvulsant drug in animal models." | 1.39 | Does aspirin use make it harder to collect seizures during elective video-EEG telemetry? ( Caylor, LM; Doherty, MJ; Godfred, RM; Haltiner, AM; Parikh, MS; Sepkuty, JP, 2013) |
| " This study was designed to assess the antiepileptic activity of aspirin and to investigate the potentiation of its activity in combination with a subconvulsive dose of lamotrigine." | 1.32 | Evaluation of antiepileptic activity of aspirin in combination with newer antiepileptic lamotrigine in mice. ( Anuradha, K; Pandhi, P; Tandon, M, 2003) |
| "Shortly after a generalized tonic-clonic seizure he passed several tablets in his stool." | 1.31 | Exchange transfusion in severe infant salicylism. ( Foltin, G; Hamilton, R; Hoffman, RS; Howland, MA; Manikian, A; Stone, S, 2002) |
| "In MES seizures significant protection was seen with aspirin 100 mg/kg where as higher dose of aspirin 500 mg/kg was required to elicit maximum protection against PTZ seizures." | 1.31 | Aspirin modulates the anticonvulsant effect of diazepam and sodium valproate in pentylenetetrazole and maximal electroshock induced seizures in mice. ( Gupta, YK; Srivastava, AK, 2001) |
| "COX-2 selective inhibitors induced the seizure at earlier onset and more severe mortality within the first hour than indomethacin and aspirin." | 1.30 | Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus. ( Baik, EJ; Kim, EJ; Lee, SH; Moon, C, 1999) |
| "The reasons given for treating fever were to make the child comfortable (99%), to prevent seizures (63%), and to satisfy parents (44%)." | 1.27 | House officer management of the febrile child. A survey. ( Herskowitz, L; Weiss, J, 1983) |
| "Cerebral involvement associated with juvenile rheumatoid arthritis is rare." | 1.27 | Cerebral infarction in juvenile rheumatoid arthritis. ( Chand, RP; Chuah, SP; Gururaj, AK, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (43.64) | 18.7374 |
| 1990's | 6 (10.91) | 18.2507 |
| 2000's | 11 (20.00) | 29.6817 |
| 2010's | 10 (18.18) | 24.3611 |
| 2020's | 4 (7.27) | 2.80 |
| Authors | Studies |
|---|---|
| Chu, CH | 1 |
| Sung, CC | 1 |
| Hu, CF | 1 |
| Chen, SJ | 1 |
| Yeom, S | 1 |
| Comi, AM | 3 |
| Arnesen, RA | 1 |
| Barbour, KK | 1 |
| Wu, A | 1 |
| Yozawitz, EG | 1 |
| Nelson, A | 1 |
| Wolf, SM | 1 |
| McGoldrick, PE | 1 |
| Basma, N | 1 |
| Grinspan, ZM | 1 |
| Booker, WA | 1 |
| Zhu, K | 1 |
| Hu, M | 1 |
| Yuan, B | 1 |
| Liu, JX | 1 |
| Liu, Y | 1 |
| Kumar, R | 1 |
| Brohi, H | 1 |
| Mughul, A | 1 |
| Day, AM | 1 |
| Hammill, AM | 1 |
| Juhász, C | 1 |
| Pinto, AL | 1 |
| Roach, ES | 1 |
| McCulloch, CE | 1 |
| Triana Junco, PE | 1 |
| Sánchez-Carpintero, I | 1 |
| López-Gutiérrez, JC | 1 |
| Sathishkumar, D | 1 |
| George, R | 1 |
| Irodi, A | 1 |
| Thomas, M | 1 |
| Selves, A | 1 |
| Ruiz, S | 1 |
| Crognier, L | 1 |
| Conil, JM | 1 |
| Bonneville, F | 1 |
| Georges, B | 1 |
| Dupuy, M | 1 |
| Fourcade, O | 1 |
| Geeraerts, T | 1 |
| Myles, PS | 1 |
| Smith, JA | 1 |
| Forbes, A | 1 |
| Silbert, B | 1 |
| Jayarajah, M | 1 |
| Painter, T | 1 |
| Cooper, DJ | 1 |
| Marasco, S | 1 |
| McNeil, J | 1 |
| Bussières, JS | 1 |
| McGuinness, S | 1 |
| Byrne, K | 1 |
| Chan, MT | 1 |
| Landoni, G | 1 |
| Wallace, S | 1 |
| de Leon, J | 1 |
| Kiesel, JL | 1 |
| Fleming, MW | 1 |
| Strobl, B | 1 |
| Ma, L | 1 |
| Cui, XL | 1 |
| Wang, Y | 1 |
| Li, XW | 1 |
| Yang, F | 1 |
| Wei, D | 1 |
| Jiang, W | 1 |
| Godfred, RM | 1 |
| Parikh, MS | 1 |
| Haltiner, AM | 1 |
| Caylor, LM | 1 |
| Sepkuty, JP | 1 |
| Doherty, MJ | 1 |
| Manikian, A | 1 |
| Stone, S | 1 |
| Hamilton, R | 1 |
| Foltin, G | 1 |
| Howland, MA | 1 |
| Hoffman, RS | 1 |
| Viossat, B | 1 |
| Daran, JC | 1 |
| Savouret, G | 1 |
| Morgant, G | 1 |
| Greenaway, FT | 1 |
| Dung, NH | 1 |
| Pham-Tran, VA | 1 |
| Sorenson, JR | 1 |
| Tandon, M | 1 |
| Anuradha, K | 1 |
| Pandhi, P | 1 |
| Bartlett, D | 1 |
| Rho, M | 1 |
| Renda, J | 1 |
| Scheepers, M | 1 |
| Pearson, A | 1 |
| Michaelides, M | 1 |
| Röggla, G | 1 |
| Moser, B | 1 |
| Rosenzweig, I | 1 |
| Manford, M | 1 |
| Emele, JF | 1 |
| Shanaman, JE | 1 |
| Berlin, CM | 1 |
| Kang, ES | 1 |
| Olson, G | 1 |
| Jabbour, JT | 1 |
| Solomon, SS | 1 |
| Heimberg, M | 1 |
| Sabesin, S | 1 |
| Griffith, JF | 1 |
| Weiss, J | 1 |
| Herskowitz, L | 1 |
| Inoue, F | 1 |
| Walsh, RJ | 1 |
| Climax, J | 1 |
| Sewell, RD | 1 |
| Chen, CS | 1 |
| Aberdeen, GC | 1 |
| Wali, RS | 1 |
| Patil, PA | 1 |
| Gould, RJ | 1 |
| Black, K | 1 |
| Pavlakis, SG | 1 |
| Kamei, C | 1 |
| Sugimoto, Y | 1 |
| Ohishi, H | 1 |
| Okumura, Y | 1 |
| Kitazumi, K | 1 |
| Maria, BL | 1 |
| Neufeld, JA | 1 |
| Rosainz, LC | 1 |
| Drane, WE | 1 |
| Quisling, RG | 1 |
| Ben-David, K | 1 |
| Hamed, LM | 1 |
| Sánchez-Hernandez, MC | 1 |
| Delgado, J | 1 |
| Navarro, AM | 1 |
| Orta, JC | 1 |
| Hernandez, M | 1 |
| Conde, J | 1 |
| Baik, EJ | 1 |
| Kim, EJ | 1 |
| Lee, SH | 1 |
| Moon, C | 1 |
| Najbauer, J | 1 |
| Schuman, EM | 1 |
| Mamelak, AN | 1 |
| Srivastava, AK | 1 |
| Gupta, YK | 1 |
| Porter, J | 1 |
| Jick, H | 1 |
| Boréus, LO | 1 |
| Livingston, S | 1 |
| Pauli, LL | 1 |
| Pavesio, D | 1 |
| Mora, P | 1 |
| Rossi, E | 1 |
| Ichiyama, T | 1 |
| Houdou, S | 1 |
| Tomita, Y | 1 |
| Yoshioka, K | 1 |
| Ohno, K | 1 |
| Gururaj, AK | 1 |
| Chand, RP | 1 |
| Chuah, SP | 1 |
| Brown, DC | 1 |
| Savage, JM | 1 |
| Vida, JA | 1 |
| Samour, CM | 1 |
| O'Dea, MH | 1 |
| Wang, TS | 1 |
| Wilson, J | 1 |
| Brett, EM | 1 |
| Done, AK | 2 |
| Temple, AR | 1 |
| Coldwell, BB | 1 |
| Boyd, EM | 1 |
| Meloff, K | 1 |
| Stanfield, JP | 1 |
| Pifferi, G | 1 |
| Consonni, P | 1 |
| Banfi, S | 1 |
| Diena, A | 1 |
| Galanda, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Local Tranexamic Acid on Post-operative Edema and Ecchymosis in Eyelid Surgery[NCT04951128] | Phase 4 | 50 participants (Anticipated) | Interventional | 2021-08-01 | Not yet recruiting | ||
| Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial[NCT03364491] | Phase 3 | 11,000 participants (Actual) | Interventional | 2018-03-15 | Completed | ||
| Tranexamic Acid to Prevent OpeRation in Chronic Subdural Hematoma. A Double-blind, Placebo-controlled, Multicentre, Randomized Controlled Clinical Trial[NCT03582293] | Phase 3 | 140 participants (Anticipated) | Interventional | 2018-06-19 | Recruiting | ||
| DEPOSITION: Pilot Study Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery[NCT03376061] | Phase 4 | 97 participants (Actual) | Interventional | 2017-12-21 | Completed | ||
| Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery (DEPOSITION) Study[NCT03954314] | Phase 3 | 3,242 participants (Actual) | Interventional | 2019-09-17 | Terminated (stopped due to Upon the Data Safety Monitoring Board review of the interim analysis (75% of participants have finished their follow-up) on November 17, 2023, they made a recommendation to stop recruitment into the trial.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
[Key secondary outcome] Change in hemoglobin from the most recent measured before delivery to lowest measured in the 48 hours after delivery (NCT03364491)
Timeframe: from 4 weeks before delivery to 48 hours postpartum
| Intervention | grams per deciliter (Mean) |
|---|---|
| Tranexamic Acid | -1.8 |
| Placebo | -1.9 |
Mother's length of stay from delivery to discharge (NCT03364491)
Timeframe: Until hospital discharge, an average of 3 days
| Intervention | days (Median) |
|---|---|
| Tranexamic Acid | 3 |
| Placebo | 3 |
(NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 35 |
| Placebo | 32 |
This is the number of mothers who were treated with any amount of open-label TXA (not blinded study drug) or another antifibrinolytic (eg., Amicar) (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 108 |
| Placebo | 109 |
This is the number of mothers who required any of the following types of surgical procedures to control bleeding: laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 233 |
| Placebo | 231 |
[Key secondary outcome] This is the number of mothers who received treatments and interventions to control bleeding such as: uterotonics such as prostaglandins or methergine, but excluding oxytocin; open label TXA or other antifibrinolytics; transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets or administration of any factor concentrates; laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 892 |
| Placebo | 986 |
Participants were categorized according to the amount of packed red blood cells or whole blood transfused, either as 0 to 3 units, or 4 or more units (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 20 |
| Placebo | 19 |
This is the number of mothers who received during the first 7 days after delivery a transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets, or received any factor concentrates (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 29 |
| Placebo | 31 |
This is the number of mothers who were treated with uterotonics such as prostaglandins or methergine, but excluding oxytocin, from delivery through 48 hours after delivery. (NCT03364491)
Timeframe: within 48 hours postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 649 |
| Placebo | 732 |
[Key secondary outcome] This is the number of mothers who experienced a thromboembolic event, ischemic stroke, or myocardial infarction during the 6 weeks after delivery. (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 12 |
| Placebo | 13 |
[Major secondary outcome] The surgeon or anesthesiologist estimated the blood loss during the delivery in milliliters, which was recorded in the anesthesia record and/or operative report (NCT03364491)
Timeframe: From skin incision to transfer from operating room, average of 1 hour
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 339 |
| Placebo | 368 |
Participants were monitored from delivery until hospital discharge or 7 days after delivery (postpartum), whichever is sooner. This is the number of mothers who died for any reason, or had a blood transfusion of 1 or more units (of packed red blood cells, including whole blood or cell saver). (NCT03364491)
Timeframe: by hospital discharge or by 7 days postpartum, whichever is sooner
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 201 |
| Placebo | 233 |
[Key Secondary Outcome] This is the number of mothers who experienced any of the following infectious complications in the 6 weeks after delivery: endometritis, surgical site infection, pelvic abscess (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 162 |
| Placebo | 125 |
This is the number of mothers who experienced seizure activity, confirmed by central review, whose onset is after enrollment (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 2 |
| Placebo | 0 |
Plasma TxA concentrations measured from blood samples taken upon arrival in the ICU (NCT03376061)
Timeframe: on arrival in ICU within 3 hours
| Intervention | microgram per milliliter per kilogram (Mean) |
|---|---|
| Topical TxA (Intervention) | 0.58 |
| Intravenous TxA (Control) | 1.10 |
Number of hours participants spent in the intensive care unit (ICU) (NCT03376061)
Timeframe: Number of hours spent in ICU from arrival to exit (collected at the Post-Operative Visit).
| Intervention | hours (Median) |
|---|---|
| Topical TxA (Intervention) | 23 |
| Intravenous TxA (Control) | 26 |
Cumulative volume (mL) of fluid collected from mediastinal drainage tubes 24 hours after the surgical procedure (NCT03376061)
Timeframe: Fluid collected in the first 24 hours after the surgical procedure
| Intervention | mL (Median) |
|---|---|
| Topical TxA (Intervention) | 500 |
| Intravenous TxA (Control) | 540 |
The occurrence of death due to any cause (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Topical TxA (Intervention) | 1 |
| Intravenous TxA (Control) | 1 |
Patients requiring a red blood cell transfusion (NCT03376061)
Timeframe: Intra-operative and post-operative RBC transfusions
| Intervention | Participants (Count of Participants) |
|---|---|
| Topical TxA (Intervention) | 19 |
| Intravenous TxA (Control) | 23 |
Occurrence of re-operation for the purpose of bleeding or cardiac tamponade (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Topical TxA (Intervention) | 0 |
| Intravenous TxA (Control) | 1 |
Patients experiencing a post-operative seizure (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Topical TxA (Intervention) | 0 |
| Intravenous TxA (Control) | 1 |
6 reviews available for aspirin and Seizures
| Article | Year |
|---|---|
Updates on Sturge-Weber Syndrome.
Topics: Aspirin; Brain; Humans; Seizures; Stroke; Sturge-Weber Syndrome | 2022 |
Hypertensive Disorders of Pregnancy.
Topics: Anticonvulsants; Antihypertensive Agents; Aspirin; Chronic Disease; Delivery, Obstetric; Eclampsia; | 2020 |
Preventive treatment with oral sirolimus and aspirin in a newborn with severe Sturge-Weber syndrome.
Topics: Administration, Oral; Aspirin; Drug Therapy, Combination; Electroencephalography; Humans; Infant, Ne | 2019 |
Presentation, diagnosis, pathophysiology, and treatment of the neurological features of Sturge-Weber syndrome.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Aspirin; Brain; Diagnosis, Differential; D | 2011 |
Advances in pediatric pharmacology and toxicology.
Topics: Animals; Anti-Bacterial Agents; Aspirin; Attention Deficit Disorder with Hyperactivity; Biological A | 1983 |
Treatment of salicylate poisoning.
Topics: Acetaminophen; Acid-Base Equilibrium; Acidosis; Acute Kidney Injury; Alkalosis, Respiratory; Aspirin | 1971 |
1 trial available for aspirin and Seizures
| Article | Year |
|---|---|
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
48 other studies available for aspirin and Seizures
| Article | Year |
|---|---|
Neonatal seizure caused by periventricular leukomalacia resulting from maternal protein S deficiency and treated with aspirin.
Topics: Aspirin; Epilepsy; Humans; Infant, Newborn; Leukomalacia, Periventricular; Protein S Deficiency; Sei | 2022 |
Multicenter Assessment of Sturge-Weber Syndrome: A Retrospective Study of Variations in Care and Use of Natural History Data.
Topics: Aspirin; Child; Epilepsy; Female; Glaucoma; Humans; Male; Retrospective Studies; Seizures; Sturge-We | 2023 |
Aspirin attenuates spontaneous recurrent seizures in the chronically epileptic mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Epilepsy, Temporal Lobe; Female; Hippocam | 2017 |
Unilateral Thalamic Infarct Presenting as a Convulsive Seizure.
Topics: Aspirin; Atorvastatin; Cerebral Angiography; Cerebral Infarction; Humans; Hydrocephalus; Levetiracet | 2017 |
Hypothesis: Presymptomatic treatment of Sturge-Weber Syndrome With Aspirin and Antiepileptic Drugs May Delay Seizure Onset.
Topics: Anticonvulsants; Aspirin; Disease Progression; Humans; Infant; Platelet Aggregation Inhibitors; Seiz | 2019 |
PHACES syndrome with moyamoya vasculopathy - a case report.
Topics: Anticonvulsants; Aortic Coarctation; Aspirin; Brain Ischemia; Child, Preschool; Eye Abnormalities; F | 2013 |
[Aspirin and its danger: Reye syndrome in young adult].
Topics: Acyclovir; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Aspirin; Brain Edema; Coma; De | 2013 |
Valproic acid toxicity associated with low dose of aspirin and low total valproic acid levels: a case report.
Topics: Aspirin; Dose-Response Relationship, Drug; Drug Interactions; Drug-Related Side Effects and Adverse | 2009 |
Aspirin attenuates spontaneous recurrent seizures and inhibits hippocampal neuronal loss, mossy fiber sprouting and aberrant neurogenesis following pilocarpine-induced status epilepticus in rats.
Topics: Animals; Aspirin; Cell Death; Cell Proliferation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase | 2012 |
Does aspirin use make it harder to collect seizures during elective video-EEG telemetry?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Electroencephalography; Female; Humans; Male | 2013 |
Exchange transfusion in severe infant salicylism.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Overdose; Exchange Transfusion, Whole Blood; | 2002 |
Low-temperature (180 K) crystal structure, electron paramagnetic resonance spectroscopy, and propitious anticonvulsant activities of CuII2(aspirinate)4(DMF)2 and other CuII2(aspirinate)4 chelates.
Topics: Animals; Anticonvulsants; Aspirin; Cold Temperature; Copper; Crystallization; Crystallography, X-Ray | 2003 |
Evaluation of antiepileptic activity of aspirin in combination with newer antiepileptic lamotrigine in mice.
Topics: Animals; Anticonvulsants; Aspirin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Co | 2003 |
Confusion, somnolence, seizures, tachycardia? Question drug-induced hypoglycemia.
Topics: Adrenergic beta-Antagonists; Adult; Aspirin; Child; Confusion; Disorders of Excessive Somnolence; Dr | 2005 |
Pica presenting as metabolic alkalosis and seizure in a dialysis patient.
Topics: Adult; Alkalosis; Aspirin; Citrates; Drug Combinations; Female; Humans; Iron Deficiencies; Kidney Fa | 2006 |
Epileptic convulsion following aspirin withdrawal before lid surgery.
Topics: Aged; Aspirin; Ectropion; Female; Humans; Platelet Aggregation Inhibitors; Preoperative Care; Risk F | 2007 |
Seizures in a night club.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Beverages; Caffeine; Drug Interactions | 2007 |
Trouble at dinner: an unusual case of eating-induced seizures.
Topics: Aged; Anticonvulsants; Aspirin; Brain Stem Neoplasms; Carbamazepine; Drug Administration Schedule; D | 2008 |
Analgesic acitivity of namoxyrate (2-[4-biphenylyl] butyric acid 2-dimethylaminoethanol salt).
Topics: Amino Alcohols; Analgesics; Animals; Aspirin; Biphenyl Compounds; Bradykinin; Butyrates; Codeine; De | 1967 |
Development of encephalopathic features similar to Reye syndrome in rabbits.
Topics: Acetaminophen; Animals; Aspirin; Disease Models, Animal; Encephalitis; Fatty Acids, Nonesterified; F | 1984 |
House officer management of the febrile child. A survey.
Topics: Acetaminophen; Aspirin; Brain Damage, Chronic; Fever; Humans; Infant; Seizures; Surveys and Question | 1983 |
Folate supplements and phenytoin-salicylate interaction.
Topics: Adult; Aspirin; Drug Interactions; Folic Acid; Folic Acid Deficiency; Humans; Male; Phenytoin; Seizu | 1983 |
Modification of convulsive behaviour and body temperature in mice by intracerebroventricular administration of prostaglandins, arachidonic acid and the soluble acetylsalicylic acid salt lysine acetylsalicylate.
Topics: Animals; Anticonvulsants; Arachidonic Acids; Aspirin; Body Temperature; Convulsants; Lysine; Male; M | 1981 |
Potentiation of acoustic-trauma-induced audiogenic seizure susceptibility by salicylates in mice.
Topics: Acoustic Stimulation; Animals; Aspirin; Mice; Mice, Inbred BALB C; Seizures; Sodium Salicylate; Stim | 1980 |
Aspirin and anticonvulsant interaction.
Topics: Animals; Aspirin; Carbamazepine; Disease Models, Animal; Drug Synergism; Electroshock; Female; Male; | 1995 |
Neonatal cerebral arterial thrombosis: protein C deficiency.
Topics: Aspirin; Carotid Artery Thrombosis; Carotid Artery, Internal; Female; Humans; Infant, Newborn; Magne | 1996 |
Epileptogenic activity induced by combined treatment with antiinflammatory drugs and enoxacin and its inhibition by a calcium antagonist, nicardipine.
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; A | 1996 |
Central nervous system structure and function in Sturge-Weber syndrome: evidence of neurologic and radiologic progression.
Topics: Adolescent; Adult; Age of Onset; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain; Cerebrovas | 1998 |
Seizures induced by NSAID.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Indomethacin; Male; Seizures | 1999 |
Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus.
Topics: Animals; Aspirin; Cell Death; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibito | 1999 |
The aspirin metabolite sodium salicylate causes focal cerebral hemorrhage and cell death in rats with kainic acid-induced seizures.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Death; Cerebral Hemorrhage; Contrain | 2000 |
Aspirin modulates the anticonvulsant effect of diazepam and sodium valproate in pentylenetetrazole and maximal electroshock induced seizures in mice.
Topics: Animals; Anticonvulsants; Aspirin; Diazepam; Male; Mice; Pentylenetetrazole; Prostaglandins; Seizure | 2001 |
Drug-induced anaphylaxis, convulsions, deafness, and extrapyramidal symptoms.
Topics: Anaphylaxis; Anti-Bacterial Agents; Aspirin; Basal Ganglia Diseases; Deafness; Drug-Related Side Eff | 1977 |
[Treatment: fever depressive measures].
Topics: Acetaminophen; Analgesics; Aspirin; Child; Cryotherapy; Humans; Seizures; Seizures, Febrile | 1977 |
Letter: Treatment of "febrile seizures".
Topics: Aspirin; Child; Drug Administration Schedule; Fever; Humans; Phenobarbital; Placebos; Seizures; Term | 1976 |
[Use of lysine acetylsalicylate in the prevention of febrile convulsions].
Topics: Aspirin; Child, Preschool; Fever; Humans; Infant; Lysine; Seizures | 1976 |
Cerebral venous thrombosis associated with recurrent epilepsy-like attacks.
Topics: Aspirin; Child; Female; Humans; Intracranial Embolism and Thrombosis; Radiography; Seizures | 1989 |
Cerebral infarction in juvenile rheumatoid arthritis.
Topics: Arthritis, Juvenile; Aspirin; Cerebral Infarction; Female; Humans; Infant; Phenytoin; Radiography; S | 1988 |
Therapeutic aspirin overdose in a three-year-old boy.
Topics: Aspirin; Child, Preschool; Diazepam; Fever; Humans; Male; Seizures | 1987 |
Analgesics. 2. Selected 5-substituted 5-(1-phenylethyl)barbituric acids.
Topics: Administration, Oral; Aminopyrine; Analgesics; Animals; Aspirin; Barbiturates; Central Nervous Syste | 1974 |
The management of febrile convulsions.
Topics: Administration, Oral; Aspirin; Child, Preschool; Diazepam; Fever; Humans; Infant; Injections, Intram | 1973 |
Treatment of febrile convulsions.
Topics: Anticonvulsants; Aspirin; Child; Child, Preschool; Diazepam; Epilepsy, Temporal Lobe; Fever; Humans; | 1974 |
Antipyretics.
Topics: Acetaminophen; Analgesics; Aspirin; Child; Health Education; Humans; Indomethacin; Mefenamic Acid; P | 1972 |
The acute rectal toxicity of acetylsalicylic acid.
Topics: Adrenal Glands; Animals; Aspirin; Ataxia; Body Weight; Brain; Coma; Diarrhea; Diuresis; Dyspnea; Fee | 1966 |
Seizures and fever.
Topics: Acetaminophen; Acidosis, Respiratory; Age Factors; Alkalosis, Respiratory; Aspirin; Brain Diseases; | 1971 |
Fever in children in the tropics.
Topics: Anti-Bacterial Agents; Aspirin; Child; Child, Preschool; Chloroquine; Fever; Humans; Hypothermia; Ph | 1969 |
2,3-benzoxazines. IX. Synthesis and central nervous system depressant activity of some 3,6- and 3,7-disubstituted 1H-3,4-dihydro-2,3-benzoxazines.
Topics: Analgesia; Animals; Aspirin; Ataxia; Barbiturates; Central Nervous System; Chlordiazepoxide; Chlorpr | 1969 |
[Remarks on the administration of acylpyrin].
Topics: Aspirin; Child, Preschool; Female; Humans; Male; Poisoning; Salicylates; Seizures | 1969 |